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Summary
The phosphatidylinositol 3# kinase (PI3#K) pathway, which regulates cell survival, is antagonized by the PTEN tumor sup-
pressor. The regulation of PTEN is unclear. A genetic screen of Drosophila gain-of-function mutants identified DJ-1 as a
suppressor of PTEN function. In mammalian cells, DJ-1 underexpression results in decreased phosphorylation of PKB/
Akt, while DJ-1 overexpression leads to hyperphosphorylation of PKB/Akt and increased cell survival. In primary breast
cancer samples, DJ-1 expression correlates negatively with PTEN immunoreactivity and positively with PKB/Akt hyper-
phosphorylation. In 19/23 primary non-small cell lung carcinoma samples, DJ-1 expression was increased compared to
paired nonneoplastic lung tissue, and correlated positively with relapse incidence. DJ-1 is thus a key negative regulator
of PTEN that may be a useful prognostic marker for cancer.S I G N I F I C A N C E
Our work is the first evidence that DJ-1 functions in the PI3#K survival pathway as a negative regulator of PTEN-mediated tumor
suppression. Breast cancer samples with high levels of PKB/Akt phosphorylation also show elevated DJ-1 expression, and lung
cancer patients with high levels of DJ-1 have a poor prognosis. DJ-1 may thus be useful as a prognostic marker for cancer patients,
and may represent a valuable new target for cancer therapy.Introduction
Cells stimulated by growth factors such as epidermal growth
factor (EGF) activate the phosphatidylinositol-3 kinase (PI3#K)
signaling pathway (Burgering and Coffer, 1995). Activated
PI3#K catalyzes the phosphorylation of phosphatidylinositol
(4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-tris-
phosphate (PIP3) (Fruman et al., 1998). PIP3 in turn recruits
PIP3-dependent kinase (PDK), which phosphorylates and acti-
vates the survival kinase, protein kinase B (PKB/Akt) (Alessi et
al., 1997; Stokoe et al., 1997). The PI3#K pathway is negatively
regulated by the dephosphorylation of PIP3 mediated by the
lipid phosphatase activity of the tumor suppressor PTEN (Mae-
hama and Dixon, 1998; Myers et al., 1998; Stambolic et al.,
1998; Sun et al., 1999).
PTEN (MMAC/TEP1) is one of the most frequently mutated
tumor suppressor genes in human cancer (Cantley and Neel,
1999). Germline mutations of PTEN result in Cowden syndrome
(Liaw et al., 1997), Bannyan-Zonana syndrome (Marsh et al.,
1997), or Lhermitte-Duclos disease (Iida et al., 1998), disorders
characterized by the development of benign hamartomas and
an increased risk of thyroid, breast, uterine, and skin neo-
plasms (Eng and Peacocke, 1998). Pten+/− mice are highly sus-
ceptible to tumor development in various tissues (Di CristofanoCANCER CELL : MARCH 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INet al., 1998; Podsypanina et al., 1999; Stambolic et al., 2000;
Suzuki et al., 1998). Fibroblasts from Pten−/− mice are resistant
to various apoptotic stimuli and exhibit hyperphosphorylation
and activation of PKB/Akt (Stambolic et al., 1998; Sun et al.,
1999). These data indicate that PTEN exerts its tumor suppres-
sor activity by inhibiting PKB/Akt-mediated cell survival.
The PI3#K, PKB/Akt, and PTEN signaling pathways are con-
served throughout evolution (Bohni et al., 1999; Cassada and
Russell, 1975; Gottlieb and Ruvkun, 1994), a fact that allowed
us to use a Drosophila melanogaster model system to study
PTEN regulation. We identified genes with modulatory effects
on PTEN signaling using a gain-of-function screen based on
the UAS-GAL4 system (Brand and Perrimon, 1993). One of the
genes that emerged from this screen encoded the Drosophila
homolog of mammalian DJ-1.
DJ-1 (CAP1/RS/PARK7) was originally cloned as a putative
oncogene capable of transforming NIH-3T3 cells in coopera-
tion with H-ras (Nagakubo et al., 1997), a protein expressed in
sperm (Wagenfeld et al., 1998), and a regulator of RNA-protein
interactions (Hod et al., 1999). DJ-1 has also been isolated as
a gene associated with autosomal early-onset Parkinson’s dis-
ease (PD) (Bonifati et al., 2003b). To date, mutations of the DJ-1
locus, such as a deletion of the first five exons (Bonifati et al.,C. DOI 10.1016/j.ccr.2005.02.010 263
A R T I C L EFigure 1. Interaction between PTEN and DJ-1 in
the Drosophila eye
A–C: Scanning electron micrographs (SEMs)
showing the normal eye disc of an adult WT fly
(A), and the smaller, rougher eye discs of flies
overexpressing dPTEN controlled by either the
GMR promoter (B) or the eyeless promoter (C).
D: SEM of the eye of progeny of a cross of GMR-
PTEN flies to P element line l(2)k04204. Increased
roughness and a slight decrease in eye size are
observed.
E: SEM of fly eye resulting from overexpression of
human DJ-1 controlled by the eyeless promoter
(ey-GAL4/UAS-DJ-1). No gross eye abnormalities
are apparent.
F: SEM of fly eye resulting from coexpression of
PTEN and DJ-1 controlled by the eyeless pro-
moter (ey-GAL4-UAS-dPTEN/UAS-DJ-1). The PTEN-
induced phenotype is almost completely
rescued.
G: Western blot of endogenous or transgenic
expression of dPTEN in 3rd instar larvae of WT
flies or the indicated transgenic flies.2003b), a mutation (L166P) which occurs in the C-terminal he-
lix of DJ-1 (Bonifati et al., 2003b; Tao and Tong, 2003), and
mutations in exon 1, intron 4, and exon 5 (Tan et al., 2004),
have been identified in various PD patients.
X-ray crystallographic examination of DJ-1 structure indi-
cates that it exists as a dimer (Tao and Tong, 2003) containing
domains found in heat shock protein chaperones (Lee et al.,
2003; Quigley et al., 2003) and ThiJ/PfpI proteases (Honbou et
al., 2003; Huai et al., 2003; Lee et al., 2003; Tao and Tong,
2003; Wilson et al., 2003). Functionally, DJ-1 has been impli-
cated in fertilization (Okada et al., 2002; Wagenfeld et al., 2000;
Yoshida et al., 2003), the regulation of androgen receptor sig-
naling (Niki et al., 2003; Takahashi et al., 2001), and oxidative264stress (Canet-Aviles et al., 2004; Mitsumoto and Nakagawa,
2001; Mitsumoto et al., 2001; Takahashi-Niki et al., 2004). In
addition, DJ-1 may be involved in apoptosis induced by TRAIL
(Hod, 2004).
Several lines of evidence suggest that DJ-1 plays a role in
human tumorigenesis. First, breast cancer patients have ele-
vated levels of circulating DJ-1 and anti-DJ-1 autoantibodies
compared to healthy and non-breast cancer patients (Le Naour
et al., 2001). Secondly, DJ-1 protein is increased in primary
non-small cell lung carcinoma samples (MacKeigan et al.,
2003). Thirdly, treatment of cells from the human lung cancer
cell line NCI-H157 with paclitaxel and MEK inhibitor U0126
leads to a decrease in DJ-1 protein expression (MacKeigan etCANCER CELL : MARCH 2005
A R T I C L Eal., 2003). Nevertheless, despite these many studies, the physi-
ological role of DJ-1 is largely unknown. Here we demonstrate
that DJ-1 modulates the PI3#K survival pathway by negatively
regulating the function of the tumor suppressor gene PTEN.
Results and discussion
DJ-1 is an antagonist of PTEN function
in the Drosophila eye
In Drosophila, overexpression of dPTEN results in decreased
eye size due to a reduction in both cell size and cell prolifera-
tion (Gao et al., 2000; Goberdhan et al., 1999; Huang et al.,
1999). In our genetic screen, GMR-GAL4-mediated expression
of dPTEN (GMR-GAL4/UAS-dPTEN) in the eye imaginal disc
resulted in a 30% decrease in eye size compared to controls
(compare Figures 1A and 1B). Higher levels of dPTEN expres-
sion directed by the stronger eyeless promoter (ey-GAL4/UAS-
dPTEN) caused an 80% reduction in eye size (Figure 1C). The
expression levels of dPTEN in wild-type (WT) flies and overex-
pressing mutants were confirmed by Western blotting of larval
protein lysates (Figure 1G). While dPTEN was more markedly
enhanced in ey-GAL4/UAS-dPTEN flies than in GMR-GAL4/
UAS-dPTEN flies, the former exhibited high lethality such that
we used the latter for the genetic screen. GMR-GAL4/UAS-
dPTEN flies were crossed to a collection of 1145 P element
lines, each harboring a heterozygous deletion of a single gene
via P element insertion (Spradling et al., 1999). F1 progeny from
these crosses were generated, and the size and morphology
of their eyes were compared to those of the parental GMR-
GAL4/UAS-dPTEN flies. In this way, individual genes disrupted
by P element mutations were evaluated for their ability to mod-
ify the phenotype caused by dPTEN overexpression.
When GMR-GAL4/UAS-dPTEN was crossed to P element
I(2)k04204, a smaller, rougher eye was observed (Figure 1D;
compare with 1B), indicating that the gene mutated by this P
element was an antagonist of PTEN function. The gene dis-
rupted in P element line I(2)k04204 was identified as the Dro-
sophila homolog of DJ-1. While no abnormal eye phenotype
was observed when human DJ-1 was overexpressed in flies
using the eyeless promoter (ey-GAL4/UAS-DJ-1) (Figure 1E),
overexpression of human DJ-1 cDNA in the germline driven
by the armadillo promoter (Vincent et al., 1994) rescued the
homozygous lethality of the P element line (data not shown),
confirming the identity of the P element mutation. To investi-
gate the genetic interaction between DJ-1 and PTEN in Dro-
sophila, ey-GAL4/UAS-DJ-1 flies were crossed to ey-GAL4/
UAS-dPTEN flies. Coexpression of PTEN and DJ-1 resulted in
suppression of the dPTEN-induced eye phenotype (Figure 1F;
compare with 1C). These results suggest that DJ-1 functions
as an antagonist of dPTEN suppressor gene function in the
fly eye.
DJ-1 rescues PTEN-induced cell death and increases
the expression of PI3#K downstream effectors
Transient transfection of human PTEN cDNA in NIH-3T3 fibro-
blasts results in decreased cell viability, indicating that the sup-
pression of cell survival caused by PTEN is sufficient to induce
cell death (Stambolic et al., 1998). To evaluate the ability of
DJ-1 to alter PTEN-induced cell death, we cotransfected NIH-
3T3 cells with human PTEN and DJ-1 and assessed the viabil-
ity of these cells using a β-galactosidase staining method. AsCANCER CELL : MARCH 2005Figure 2. DJ-1 rescues PTEN-induced cell death
A: Restoration of viability. NIH-3T3 cells were transfected with constructs
expressing the indicated proteins in the presence of trace amounts of a
β-galactosidase expression construct. At 48 hr posttransfection, cells were
fixed and stained with X-gal, and surviving blue cells were counted. Data
are expressed as % viability relative to the control transfection and repre-
sent the mean ± SE of 5 independent experiments.
B: Requirement for PTEN. Pten+/− (green) and Pten−/− (yellow) MEFs were
infected with retrovirus bearing either empty IRES vector or IRES-DJ-1. After
48 hr, the infected cells were treated with 5 M staurosporine. After 24 hr,
the viability of treated, infected cells was determined by 7-AAD staining.
Results are expressed as the % viability relative to untreated control infec-
tants and represent the mean ± SE of 3 independent experiments.
C: Resistance to apoptotic stimuli. NIH-3T3-lacZ (blue) and NIH-3T3-DJ-1
(red) cells were treated with the indicated apoptotic stimuli as described
in the Experimental Procedures. Cell viability (%) was determined 24 hr later
by 7-AAD staining and normalized to the untreated control (5% FCS). Re-
sults shown are the mean ± SE of 3 independent experiments.265
A R T I C L EFigure 3. DJ-1 increases the activation of PI3#K
downstream effectors
A: Increased phosphorylation of overexpressed
PKB/Akt. Western blot analysis of lysates of COS7
cells transiently transfected with HA-PKB/Akt in
the absence or presence of FLAG-hDJ-1. Trans-
fected cells were serum-starved (0.5% FCS) or
left unstarved (US), and either left untreated or
treated with IGF-1 (50 ng/ml) with or without
Wortmannin (W; 100 nM) as described in the Ex-
perimental Procedures. Antibodies recognizing
total PKB/Akt (PKB) and PKB/Akt phosphorylated
on S473 (S473 P-PKB) were used.
B: Decreased phosphorylation of endogenous
PKB/Akt in response to DJ-1 knockdown. West-
ern blot analysis of lysates of A549 cells, or A549
cells stably transfected with either a missense
control of DJ-1-specific siRNA B, the DJ-1-spe-
cific siRNA sequences A or B, or control GAPDH
siRNA (see Experimental Procedures). Antibod-
ies specific for the indicated proteins were used,
with washing and reprobing as necessary.
C: Unchanged endogenous PKB/Akt phosphor-
ylation in the absence of PTEN. Western blot
analysis of lysates of Pten+/− or −/− MEFs stably
infected with either DJ-1-specific siRNAs A or B,
or a missense control for B. Other controls in-
cluded a mock transfection (no vector), and a
transfection of empty vector (pSuper-retro-
puro). Antibodies specific for the indicated pro-
teins were used, with washing and reprobing
as necessary.
D: Increased phosphorylation of endogenous
PKB/Akt. Western blot of lysates of stably trans-
fected NIH-3T3-DJ-1 cells (right) or control NIH-
3T3-lacZ cells (left) starved, treated, and ana-
lyzed as in A.
E: Upregulation of cyclin D1 and GSK-3-β. West-
ern blots of lysates of the NIH-3T3-lacZ and NIH-
3T3-DJ-1 cells in D analyzed with antibodies spe-
cific for the indicated proteins, with washing
and reprobing as necessary.expected, expression of PTEN alone resulted in decreased cell
viability, and expression of DJ-1 alone had no effect on cell
survival (Figure 2A). However, coexpression of DJ-1 and PTEN
completely rescued PTEN-induced cell death.
Various cell types from Pten−/− mice show decreased sensi-
tivity to a broad range of apoptotic stimuli (Stambolic et al.,
1998). To determine the effect of DJ-1 on apoptosis, Pten−/−
and +/− cells (Stambolic et al., 1998; Suzuki et al., 1998) were
retrovirally infected with human DJ-1 and treated with 5 M
staurosporine. Pten+/− infectants expressing DJ-1 showed a
60% increase in cell survival compared to treated infected
Pten+/− cells lacking DJ-1 (Figure 2B). However, in the absence
of PTEN (Pten−/− DJ-1 infectants), no significant rescue of cell
survival was observed. We extended these observations by
generating stable NIH-3T3 lines overexpressing FLAG-tagged
human DJ-1 (NIH-3T3-DJ-1 cells), or a lacZ control (Tang et
al., 2000) (NIH-3T3-lacZ cells). The response of NIH-3T3-DJ-1
cells to a range of cellular insults was then assessed using
viability dye staining. NIH-3T3-DJ-1 cells exhibited a 40%–
50% reduction of apoptosis (compared to control NIH-3T3-266lacZ cells) in response to treatment with UV irradiation, sorbitol,
or TNF-α (Figure 2C). These results indicate that overexpres-
sion of DJ-1 renders cells resistant to various apoptotic stimuli
in a PTEN-dependent fashion.
We next investigated the effect of DJ-1 on PKB/Akt activa-
tion. PKB/Akt is highly phosphorylated in the absence of PTEN
function (Di Cristofano et al., 1998; Stambolic et al., 1998; Sun
et al., 1999; Suzuki et al., 1998). We found that transient co-
transfection of DJ-1 plus PKB/Akt into COS-7 cells caused hy-
perphosphorylation of PKB/Akt under resting (10% FCS) and
serum-starved (0.5% FCS) conditions (Figure 3A). Stimulation
of COS-7 cells with insulin-like growth factor (IGF) resulted in
a significant increase in PKB/Akt phosphorylation in the pres-
ence of DJ-1, but only a moderate increase in cells transfected
with PKB/Akt alone. Pretreatment of starved cells with the
PI3#K inhibitor Wortmannin reduced the IGF-induced increase
in PKB/Akt phosphorylation in the absence or presence of DJ-1.
This increase in phosphorylated PKB/Akt was reversed in A549
cells stably expressing either of two DJ-1-specific siRNAs that
decreased DJ-1 expression (Figure 3B). Similarly, as shown in
Figure 3C, a decrease in phosphorylated PKB/Akt was seenCANCER CELL : MARCH 2005
A R T I C L EFigure 4. DJ-1 stimulates oncogenesis and alters cell cycle arrest
A: Increased proliferation. NIH-3T3-lacZ and NIH-3T3-DJ-1 cells were pulsed
with [3H] thymidine for 18 hr prior to measurement of [3H] thymidine incor-
poration in extracts. Results shown are the mean ± SE of 4 independent ex-
periments.
B: Increased growth in soft agar. NIH-3T3-lacZ or NIH-3T3-DJ-1 cells were
seeded in 0.6% agar and colonies were scored 14 days later. Results shown
are mean ± SE of 3 independent experiments.
C: Enhanced tumorigenesis in nude mice. Nude mice (5 per group; 4–6
weeks old) were injected with either NIH-3T3-lacZ or NIH-3T3-DJ-1 cells
(1.0 × 106), and tumor weights were determined 9 days later. Results shown
are the mean tumor weights (g) ± SE.
D: Altered cell cycle arrest. NIH-3T3-lacZ cells (left panels) or NIH-3T3-DJ-1
cells (right panels) were cultured for 24 hr with (top panels) or without (bot-
tom panels) 0.5% FCS. Cell cycle distribution was analyzed by propidium
iodide (50 g/ml) staining. The percentages of cells in the G0/G1, S, or G2/
M phase and in apoptosis were determined by flow cytometry and are
indicated within each panel.when murine DJ-1 expression was decreased by siRNA in
Pten+/− immortalized mouse embryonic fibroblasts (MEFs)
(Stambolic et al., 1998). Interestingly, when this protocol was
applied to Pten−/− MEFs (Stambolic et al., 1998), the decrease
in phosphorylated PKB/Akt was not observed (Figure 3C). This
result indicates that the function of DJ-1 requires the presence
of PTEN. When we analyzed phosphorylated PKB/Akt levels in
the NIH-3T3 stable transfectants, we found that expression of
DJ-1 (but not lacZ) induced high levels of endogenous phos-
phorylated PKB/Akt (Figure 3D). Stimulation of NIH-3T3-DJ-1
cells with IGF or 10% serum caused a further increase in phos-
phorylated PKB/Akt (Figure 3D). Consistent with this elevation
in phosphorylated PKB/Akt, NIH-3T3-DJ-1 cells showed mark-
edly higher levels of phosphorylated GSK-3-β (van Weeren et
al., 1998) and cyclin D1 (Diehl et al., 1998) compared to controlCANCER CELL : MARCH 2005cells (Figure 3E). Taken together, these results indicate that
DJ-1 suppresses PTEN function and thereby profoundly affects
downstream targets of PTEN such as PKB/Akt.
DJ-1 is an oncogene
The oncogenic potential of DJ-1 was investigated by sub-
jecting the stable NIH-3T3 transfectants to several indicative
tests. Compared to NIH-3T3-lacZ cells, NIH-3T3-DJ-1 cells
showed increased proliferation as measured by 3H-thymidine
incorporation (Figure 4A), and increased colony formation in
soft agar (Figure 4B). When NIH-3T3-DJ-1 cells were subcuta-
neously injected into nude mice, significantly more tumor
growth occurred than in animals injected with NIH-3T3-lacZ
cells (Figure 4C). Because oncogenesis can also result from
dysregulation of cell cycle arrest mechanisms, and ectopic
PTEN expression can induce cell cycle arrest (Furnari et al.,
1998; Li and Sun, 1998), we examined the effect of DJ-1 on
the cell cycle. While NIH-3T3-lacZ cells underwent total G1 ar-
rest upon 24 hr serum starvation (Figure 4D, left panels), NIH-
3T3-DJ-1 cells were completely resistant to serum starvation
and retained a normal cell cycle profile (Figure 4D, right pan-
els). Our results are consistent with the previous identification
of DJ-1 as a putative oncogene that cooperates with H-ras
(Nagakubo et al., 1997), and suggest that DJ-1 can transform
cells by increasing both cell proliferation and resistance to cell
cycle arrest.
DJ-1 plays a role in the pathogenesis
of primary breast cancer
Analyses of PTEN in primary breast carcinoma specimens by
various groups have indicated that mutations of the PTEN gene
are not a major factor in the development of sporadic breast
cancers (Feilotter et al., 1999; Freihoff et al., 1999; Rhei et al.,
1997). Primary ductal adenocarcinomas that are hemizygous
for PTEN deletion, but with no structural alterations of the re-
maining allele, do not show positive immunostaining for PTEN.
This finding suggests that an epigenetic phenomenon is affect-
ing PTEN in these cases (Perren et al., 1999; Shi et al., 2003).
Others have observed that DJ-1 levels are increased in the se-
rum of breast cancer patients, and have suggested that this
protein can be used as a prognostic marker (Le Naour et al.,
2001). To investigate whether DJ-1 functions as a negative
epigenetic regulator of PTEN, we examined the expression of
DJ-1 protein, phosphorylated PKB/Akt, and PTEN in serial his-
tologic sections from 73 patients with lymph node-negative
breast cancer (Supplemental Table S1). We have previously
shown that levels of PTEN protein and phosphorylated PKB/
Akt are negatively correlated in these same samples (Shi et al.,
2003). In this study, DJ-1 expression was generally observed
in the cytoplasm of invasive breast cancer cells (Figure 5A),
while PTEN expression was absent (Figure 5B), and phosphor-
ylated PKB/Akt levels were elevated (Figure 5C). Among the 28
samples which were PTEN negative, 79% (22/28) were DJ-1
positive. However, only about half (51%) of 45 PTEN-positive
samples were DJ-1 positive (Figure 5D, p = 0.02), suggesting
that PTEN and DJ-1 are inversely associated. We note, how-
ever, that these findings do not preclude the existence in the
PTEN-positive samples of mutations in other PI3#K genes such
as PIK3CA (Lee et al., 2005; Samuels et al., 2004), which has
recently been shown to contribute to oncogenesis (Kang et al.,
2005). In support of a negative regulatory effect of DJ-1 on267
A R T I C L EFigure 5. DJ-1 expression in primary cancers
A–C: Representative immunostaining analyses
of serial sections from a single patient’s surgical
tumor specimen showing DJ-1 protein expres-
sion in the cytoplasm of the invasive breast can-
cer cells (A), the absence of PTEN expression
(B), and high levels of phosphorylated PKB/Akt
protein (C) (400× magnification).
D and E: Results from all 73 breast cancer speci-
mens were analyzed in 2 × 2 tables. There was
an inverse correlation between DJ-1 and PTEN
(D), and a positive correlation between DJ-1
and phosphorylated PKB/Akt (E); χ2 test.
F: Mean plot analyzing DJ-1 and phosphory-
lated PKB/Akt immunoreactivity score in 40 lung
cancer specimens (± SEM). There was a positive
correlation between DJ-1 and phosphorylated
PKB/Akt/; unpaired t test.
G: Scatter plots of DJ-1 immunoreactivity com-
pared to DJ-1 mRNA levels measured by real-
time RT-PCR. DJ-1 immunoreactivity correlated
positively with relative mRNA levels; unpaired t
test.
H: Real-time RT-PCR analysis of DJ-1 mRNA in 23
paired normal and lung cancer specimens. Re-
sults shown are the relative ratio of CT(DJ-1 tu-
mor):CT(DJ-1 mean of normal lung values). DJ-1
was significantly increased in tumors compared
to normal tissues; p = 0.001, Wilcoxon sign rank
test.PTEN, we found evidence for a positive relationship between
DJ-1 and phosphorylated-PKB. Fully 88% (15/17) of the phos-
phorylated PKB/Akt positive samples stained positively for
DJ-1, but only 52% of the phosphorylated PKB/Akt negative
samples were DJ-1-positive (Figure 5E, p = 0.007). In these
latter cases, we speculate that other mutations and signaling
pathways have come to dominate in the transformed cells, and
that DJ-1 is no longer the driving force behind tumorigenesis.268No correlation between DJ-1 expression and patient age, clin-
ical status, primary tumor size, ploidy, ER or PR status, or %
S phase was found (data not shown). Our results suggest a
mechanism by which DJ-1 might play a tumorigenic role in
cases where PTEN mutations are not frequently observed,
such as primary breast cancers. DJ-1 may modulate PTEN
function such that PKB/Akt becomes hyperphosphorylated
and promotes abnormal cell survival.CANCER CELL : MARCH 2005
A R T I C L EFigure 6. DJ-1 may be a prognostic marker for primary lung cancer
Cumulative incidence of risk recurrence in lung cancer patients catego-
rized by their level of DJ-1 mRNA (CT) expression. Higher CT corresponds
to lower DJ-1 expression. Tumors were dichotomized using the median CT
value as the cutoff for high and low DJ-1 expressors (see Experimental Pro-
cedures). The time to relapse was evaluated for all lung cancer patients
(A), for patients with Stage I disease (B), and for patients whose tumors
exhibited the wild-type Ras genotype (C).DJ-1 is a prognostic marker for primary lung cancer
To determine if elevated DJ-1 expression is a factor in other
types of cancers, we examined DJ-1 and phosphorylated PKB/
Akt levels in primary lung cancer samples. It was recently
shown that DJ-1 protein expression is increased in primary
non-small cell lung carcinomas (MacKeigan et al., 2003). Tis-
sue blocks from 40 primary lung cancer patients (Zhu et al.,
2004) (Supplemental Table S2) were analyzed by immunohisto-
chemistry for DJ-1 and phosphorylated PKB/Akt. Consistent
with our breast cancer findings, we found a significant correla-
tion between DJ-1 and phosphorylated PKB/Akt immunoreac-CANCER CELL : MARCH 2005tivity (Figure 5F, p = 0.045). Furthermore, DJ-1 immunoreactiv-
ity was correlated positively with DJ-1 mRNA levels as
measured by real-time RT-PCR (Figure 5G, p = 0.0018). To fur-
ther investigate the contribution of DJ-1 to lung cancer patho-
genesis, we performed real-time RT-PCR on RNA samples
from paired normal and malignant tissues from 23 patients with
non-small cell lung carcinoma (Zhu et al., 2004). In 19/23 sam-
ples, expression of DJ-1 mRNA was increased in the tumor
compared to the corresponding non-neoplastic and grossly
normal lung tissue (Figure 5H; p = 0.001); nine samples had a
greater than 2-fold increase.
We next investigated the prognostic significance of DJ-1
mRNA expression levels in the 23 tumor samples analyzed
above plus 108 additional non-small cell lung carcinoma sam-
ples (Zhu et al., 2004) (Supplemental Table S2). Two clinical
outcome measures were used: disease-free survival and inci-
dence of relapse. Overall, analysis of the association between
DJ-1 expression and the time to relapse suggested that having
a higher expression level (lower CTDJ-1, see Experimental
Procedures) of DJ-1 was an adverse prognostic factor. When
the cumulative incidence of relapse in all patients was exam-
ined, patients who had high levels of DJ-1 expression had a
significantly higher rate of relapse than patients with lower
levels of DJ-1 (Figure 6A, p = 0.027). The 3-year risk of relapse
for the group with high DJ-1 expression was 46% versus 28%
for the group with low DJ-1. A similar observation was made
when DJ-1 was evaluated as a continuous variable (data not
shown, p = 0.022), suggesting a linear relationship between
DJ-1 expression and the hazard ratio (relative risk) for relapse.
Indeed, the hazard ratio increased by 1.2-fold for each unit
increase in DJ-1 expression (data not shown).
When DJ-1 expression was analyzed by stage of cancer, we
found that the median DJ-1 expression level was higher in
Stage II and III patients compared to Stage I patients (CTDJ-1
of 15.56 versus 16.01, p = 0.032 by Wilcoxon nonparametric
test). In fact, DJ-1 appeared to have its greatest effect in Stage
I tumors, where the incidence of relapse was 45% for patients
with high DJ-1 levels as opposed to 18% for patients with
lower levels (Figure 6B, p = 0.0069). The increased proportion
of patients with higher DJ-1 levels in the Stage II and III groups
may explain the loss of prognostic significance of DJ-1 for
these patients. Alternatively, DJ-1 may have greater impact in
early stage lung cancers, before additional genetic aberrations
accumulate during tumor progression. To explore this hypothe-
sis, we analyzed DJ-1 expression levels in relation to another
putative lung cancer prognostic marker gene, Ki-ras (Iyengar
and Tsao, 2002). Indeed, DJ-1 was not prognostic for patients
whose tumors harbored Ki-ras mutations (data not shown).
However, for patients whose tumors had the wild-type Ki-ras
genotype, a higher level of DJ-1 correlated positively with an
increased risk of relapse (Figure 6C, p = 0.061). These data
indicate that DJ-1 upregulation in lung cancer may be a useful
prognostic marker, particularly for patients with wild-type Ras
and Stage I disease. Our findings also suggest that mutation
of DJ-1 may have the same biological impact as the presence
of the Ki-ras oncogene in early stage non-small cell lung
cancers.
Our study is the first demonstration that the oncogenic prop-
erties of DJ-1 are due to its effects on the PI3#K cell survival
pathway. However, the many possible pathways in which DJ-1
and PTEN could interact remain to be clarified. Loss-of-func-269
A R T I C L Etion mutations in DJ-1 have been identified in Parkinson’s dis-
ease (Bonifati et al., 2003a), and neuronal loss in Parkinson’s
patients is mainly attributed to oxidative stress (Jenner, 2003).
Significantly, DJ-1 is known to be involved in apoptosis due to
oxidative stress (Taira et al., 2004). PTEN has also been impli-
cated in oxidative stress, where its function was modulated by
exposure to peroxide (Leslie et al., 2003); however, PTEN’s role
in the oxidant-dependent pathway remains to be fully charac-
terized. It is possible that DJ-1 exerts a redox effect on PTEN
or another upstream regulator through either DJ-1’s putative
protease activity (Wilson et al., 2003) or its redox-sensitive
chaperone activity (Shendelman et al., 2004).
In conclusion, our results demonstrate that DJ-1 negatively
regulates PTEN function, and that this cell survival control
mechanism is conserved among various tissues and species.
We identified DJ-1 as a suppressor of PTEN function in the fly
eye and extended these observations to the mammalian sys-
tem. Knockdown of DJ-1 results in a decrease in phosphory-
lated PKB/Akt, while overexpression of DJ-1 is associated with
hyperphosphorylation of PKB/Akt and upregulation of down-
stream effectors that promote cell survival. We have also
shown that DJ-1 expression negatively correlates with PTEN
staining and positively correlates with phosphorylated PKB/Akt
expression in a group of primary breast cancer patients, a pop-
ulation that does not normally harbor mutations in PTEN. Fur-
thermore, we have demonstrated that DJ-1 is highly expressed
in primary lung cancers, that phosphorylated PKB/Akt corre-
lates positively with DJ-1 immunoreactivity in these tumors,
and that elevated DJ-1 is associated with a poor prognosis.
Taken together, our data suggest that overexpression of DJ-1 can
modulate PTEN tumor suppression to the point where onco-
genesis may result from upregulated PKB/Akt-mediated cell
survival.
Experimental procedures
Generation of transgenic flies
Oligonucleotide primers flanking the putative Drosophila PTEN open read-
ing frame (Gao et al., 2000; Goberdhan et al., 1999; Huang et al., 1999)
were designed (sense primer: BamHI Kozak 5#-GGA TCC ACC ATG GCC
AAC ACT ATT TCG TTA ATG TCC-3#; antisense XhoI Stop primer: 5#-CTC
GAG TCA CTC CGA TTC CCA ATC TTC CTC GCC ATC-3#). These primers
were used to amplify a 1.53 kb product from 18 hr Drosophila embryos
using the QUICK-Clone cDNA kit according to the manufacturer’s protocol
(Clontech, Palo Alto, CA). Drosophila PTEN and human DJ-1 cDNAs were
cloned into the pUAST vector (Brand and Perrimon, 1993) and injected into
w1118 (Brand and Perrimon, 1993) Drosophila embryos to generate trans-
formants. For PTEN transgenic flies, UAS-dPTEN flies were crossed to
those bearing GMR-GAL4 or ey-GAL4 (Peters et al., 2002). For adult fly
rescue experiments, UAS-DJ-1 was crossed to flies bearing arm-GAL4 (Vin-
cent et al., 1994). The arm-GAL4/UAS-DJ-1 transgene resulted in a rescue
of viability of 23%. Rescue was scored as the percentage of live flies with
a homozygous P element allele (the expected number is zero).
Drosophila Western blots
Protein extracts of 3rd instar Drosophila larvae were prepared as previously
described (Peters et al., 2002). Extracts were subjected to Western blotting
using polyclonal antibody directed against human PTEN (Stambolic et al.,
1998).
Transfections and retroviral infections
Transient transfections were carried out using Lipofectamine Plus (Invitro-
gen). For stable transfections, FLAG-hDJ-1 was cloned into pBABE-puro.
For siRNA stable transfections, A549 cells were transfected with pSilencer
(Ambion) vectors containing DJ-1-specific siRNAs (clone A target, TCT270GGG CGC ACA GAA TTT; clone B, GTA AAG TTA CAA CAC ACC) or control
GAPDH RNA. Stable transfectants were selected for 14 days in 400 g/ml
hygromycin. For murine Pten+/− and Pten−/− infectants, FLAG-hDJ-1 was
cloned into pLPC-puro-IRES-GFP, and DJ-1-specific siRNAs (clone A
target, AGG CGC GGC TGC AGT CTT TAA; clone B, GTA GCC GTG ATG
TAA TGA TTT) were cloned into pSuper-retro-puro (Oligoengine). All retro-
viruses were packaged within the ФNX-Eco cell line.
Analyses of cell death
For viability staining, NIH-3T3 cells were transfected with cDNAs encoding
PTEN and/or DJ-1 in the presence of trace amounts of a β-galactosidase
expression construct as described previously (Stambolic et al., 1998). At 48
hr posttransfection, cells were fixed and stained with X-gal. Numbers of
surviving transfected cells (blue) were counted in 10 randomly selected
fields by two researchers in a blinded fashion.
For flow cytometry, NIH-3T3 cells (1.0 × 106) were plated and treated the
next day with the following apoptotic stimuli: UV (780 J/m2), sorbitol (0.4 mM),
TNF-α (10 ng/ml) plus cycloheximide (5 g/ml), or staurosporine (5 M).
Treated cells were stained 24 hr later with 7-amino-actinomycin D (7-AAD). For
Pten+/− and −/− MEFs, infected cells were gated on GFP. Negatively staining
cells were quantified in a FACScan flow cytometer (Becton Dickinson).
COS7 cells and serum starvation
COS7 cells were transiently transfected with HA-PKB/Akt (Stambolic et al.,
1998) plus or minus human FLAG-DJ-1. Cells were either not starved or
starved for 18 hr in DMEM containing 0.5% serum. Starved and unstarved
cells were then either left untreated, treated for 20 min with IGF-1 (50 ng/ml),
or treated for 30 min with Wortmannin (100 nM), followed by a 20 min incu-
bation with IGF-1 (50 ng/ml). HA-PKB/Akt was immunoprecipitated using
an anti-HA antibody (12CA5) and analyzed by Western blotting.
Western blotting
Cells were lysed in 0.5% CHAPS buffer and subjected to Western blotting
using rabbit polyclonal anti-phosphoS473 PKB/Akt, anti-PKB/Akt, anti-
phospho-GSK-3-β, or mouse anti-cyclin D1 antibodies (all from Cell Signal-
ing); mouse anti-GSK-3-β (Transduction Labs); rabbit anti-actin, or mouse
anti-FLAG clone M5 (Sigma-Aldrich). Bound antibodies were detected by
enhanced chemiluminescence (ECL, Amersham).
Cell proliferation
Cells (1.0 × 104) were plated in quadruplicate and incubated for 12, 20, or
36 hr. For the last 12 hr of incubation, 1 µCi 3H-thymidine was added to
measure 3H-thymidine incorporation.
Growth in soft agar
Dishes (35 mm) were prepared with a lower layer of 0.6% agar (BiTek,
DIFCO). The overlay was a 0.3% agar solution containing 1.0×104 NIH-3T3-
lacZ, NIH-3T3-DJ-1, or NIH-3T3-V12-Ras (positive control) cells. After 14
days growth, colonies larger than 0.1 mm in diameter were scored as pos-
itive.
Cell cycle distribution
Cells were stained with propidium iodide (50 g/ml) and analyzed for phase
of the cell cycle by flow cytometry according to standard procedures.
Injections of nude mice
Athymic, Balb-c/nu/nu mice of 4–6 weeks of age were injected with 1.0 ×
106 NIH-3T3-lacZ cells (n = 5) or NIH-3T3-DJ-1 cells (n = 5) in 100 l PBS.
Tumor weights were measured at 9 days postinjection.
Anti-DJ-1 antibody
Rabbit antiserum was raised against purified Trx-huDJ-1 protein (Antibod-
ies, Inc., Davis, CA) and purified by preadsorption on Trx-coupled CNBr-
Sepharose 4B followed by affinity purification on GST-huDJ-1 fusion protein
coupled to CNBr-Sepharose 4B. Low-affinity antibody was eluted in a pH
5.0 buffer and stored. The high-affinity DJ-1-specific antibody used in this
study was eluted from the affinity column with 0.1M glycine (pH 2.5).
Immunohistochemistry
Archival formalin-fixed, paraffin-embedded tumor sections from primary
surgical specimens of breast cancer patients (Shi et al., 2003) and lungCANCER CELL : MARCH 2005
A R T I C L Ecancer patients (Zhu et al., 2004) were stained with antibodies recognizing
PTEN (Zymed, 1:80), phosphoS473-PKB (New England Biolabs, 1:70), or
DJ-1 (1:300) as previously described (Shi et al., 2003). After immunostaining
overnight, the slides were incubated with biotinylated secondary (anti-rab-
bit) antibodies followed by Streptavidin-HRP enzyme complex (Signet
Laboratories, Dedham, MA). Cells were visualized using AEC as the chro-
mogen, and counterstained with hematoxylin to define cellular morphology.
For lung cancer specimens, DJ-1 staining was evaluated as absent/weak
or moderate/strong and phosphorylated Akt/PKB immunoreactivity was
scored as absent (0), weak (1), moderate (2), or strong (3) by a blinded pa-
thologist.
Real-time RT-PCR quantitation of mRNA
DJ-1 mRNA expression levels in 23 paired samples of primary non-small
cell lung cancer cells and corresponding nonneoplasic lung tissues, and in
108 unpaired primary non-small cell lung cancer samples (Zhu et al., 2004),
were measured using quantitative RT-PCR as previously described (Zhu et
al., 2004). Primers used to amplify DJ-1 transcripts and give a 90 bp pro-
duct were: DJ-1 forward, GGA GAC GGT CAT CCC TGT AGA T; DJ-1 re-
verse, GCT ACA CTG TAC TGG GTC TTT TCC A. Levels of mRNA in each
sample were normalized using the calculation CT = [CT(DJ-1) − CT(18S)]
(Zhu et al., 2004). High expressors of DJ-1 were defined as CTDJ-1 % 15.9
and low expressors were defined as CTDJ-1 > 15.9, where CTDJ-1 = 15.9
was the median of all samples. Relative mRNA transcript levels in tumor
tissues and paired nonneoplastic lung tissues were calculated as previously
described (Wang et al., 2002).
Statistical methods
Statistical analyses were carried out using SAS v8.2 and S-plus software.
For analysis of immunohistochemical categorical data, the χ2 test was used.
For analysis of lung cancer immunohistochemical data, the unpaired t test
was used. The Wilcoxon sign rank test was used to analyze mRNA levels
in paired lung tissue samples and to compare DJ-1 levels between cancer
stages. The testing of the DJ-1 mRNA level as a continuous variable was
performed using the Cox proportional hazards model. The incidence of re-
lapse was estimated using the cumulative incidence approach (Kalbfleisch
and Prentice, 1980), and the difference between the low DJ-1 and high DJ-1
groups was evaluated using the log rank test.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/3/263/DC1/.
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